NEW YORK, March 22, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled
Products under development from FractalDx are anticipated to be part of the extended RenalytixAI pipeline following the introduction of KidneyIntelX in 2019 for the diagnosis of fast-progressing chronic kidney disease. RenalytixAI hopes to commercialize a range of advanced diagnostic tests that are expected to aid in accurate dosing of immune-suppression therapy and in making significant improvements in the identification of and monitoring for kidney transplant rejection.
The FractalDx technology is based primarily on sequencing biomarkers from a patient's blood using widely available instrument platforms such as Illumina sequencers.
"Our hope is that FractalDx will give us the ability to tailor immunosuppressive therapy to the personal needs of the patient. The current therapeutic practice of 'one size fits all' dosing results in unnecessary complications including infection, cancers or avoidable rejections," said Dr. Barbara Murphy, Dean for Clinical Integration and Population Health, Professor and System Chair Medicine and Nephrology, at the Icahn School of Medicine at Mount Sinai, and Chair of the Scientific Advisory Board of RenalytixAI. "We have the technology to support development of a test that will apply personalized medicine to kidney transplant patients to guide administration of immunosuppression with the aim of improving outcomes."
"There are major unmet needs that limit the survival and effectiveness of kidney transplantation. The FractalDx diagnostic program has the potential to identify patients at increased risk for poor outcomes at a stage when intervention is still possible," said Dr. Christian P. Larsen, MD, DPhil, Professor of Surgery, Division of Transplantation Emory University. "It is important that we develop the next generation of diagnostics and determine how best to incorporate them into the care team workflow to reduce risk and maximize the benefit from immunosuppressive therapy for our transplant recipients."
RenalytixAI is forming the core investigator group now, ahead of its expected initiation of the clinical validation for the first diagnostic product from the portfolio, beginning in the second half of 2019.
The initial investigator appointments include:
Kidney transplantation is on the rise in the United States and globally. From 2017 to 2018, the number of kidney transplants performed in the U.S. rose from 19,849 to 21,168.1 Contributing to the critical unmet need, approximately 7 percent of kidney transplants fail within one year, and approximately 17 percent fail within three years2 which leads to additional patient complications and growing medical treatment cost.
About Kidney Disease Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.
About RenalytixAI RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.
1 United Network for Organ Sharing (UNOS), 20192 National Kidney Foundation, 2019
View original content:http://www.prnewswire.com/news-releases/renalytixai-forms-core-investigator-group-for-kidney-transplant-advanced-diagnostic-program-300816862.html
Subscribe to our Free Newsletters!